CL2012003285A1 - Compuestos derivados de sulfonil-carbamoil-fenoxi-pirrolo-piridina, inhibidores de la actividad de proteinas anti-apoptoticas bcl-2; composicion farmaceutica; y metodo para tratar cancer de vejiga, cancer de cerebro, cancer de mama, cancer de medula osea, cancer cervical y leucemia linfocitica cronica, entre otras enfermedades. - Google Patents

Compuestos derivados de sulfonil-carbamoil-fenoxi-pirrolo-piridina, inhibidores de la actividad de proteinas anti-apoptoticas bcl-2; composicion farmaceutica; y metodo para tratar cancer de vejiga, cancer de cerebro, cancer de mama, cancer de medula osea, cancer cervical y leucemia linfocitica cronica, entre otras enfermedades.

Info

Publication number: CL2012003285A1
Authority: CL; Chile
Prior art keywords: cancer; pyrrolo; carbamoyl; sulfonyl; phenoxy
Prior art date: 2010-05-26

Application number

CL2012003285A

Other languages

English (en)

Inventor

Zhi Fu Tao

Xilu Wang

Andrew J Souers

Nathaniel D Catron

Gerard Sullivan

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-26

Filing date

2012-11-23

Publication date

2013-10-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45004346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-23 Application filed by Abbvie Inc filed Critical Abbvie Inc

2013-10-04 Publication of CL2012003285A1 publication Critical patent/CL2012003285A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
- A01N43/38—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL2012003285A 2010-05-26 2012-11-23 Compuestos derivados de sulfonil-carbamoil-fenoxi-pirrolo-piridina, inhibidores de la actividad de proteinas anti-apoptoticas bcl-2; composicion farmaceutica; y metodo para tratar cancer de vejiga, cancer de cerebro, cancer de mama, cancer de medula osea, cancer cervical y leucemia linfocitica cronica, entre otras enfermedades. CL2012003285A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34842210P	2010-05-26	2010-05-26

Publications (1)

Publication Number	Publication Date
CL2012003285A1 true CL2012003285A1 (es)	2013-10-04

Family

ID=45004346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003285A CL2012003285A1 (es)	2010-05-26	2012-11-23	Compuestos derivados de sulfonil-carbamoil-fenoxi-pirrolo-piridina, inhibidores de la actividad de proteinas anti-apoptoticas bcl-2; composicion farmaceutica; y metodo para tratar cancer de vejiga, cancer de cerebro, cancer de mama, cancer de medula osea, cancer cervical y leucemia linfocitica cronica, entre otras enfermedades.

Country Status (38)

Country	Link
US (5)	US9006247B2 (es)
EP (3)	EP2575463B1 (es)
JP (1)	JP5782508B2 (es)
KR (2)	KR101800167B1 (es)
CN (2)	CN104961771B (es)
AR (1)	AR081552A1 (es)
AU (1)	AU2011258350B2 (es)
BR (1)	BR112012029733B1 (es)
CA (1)	CA2798765C (es)
CL (1)	CL2012003285A1 (es)
CO (1)	CO6640275A2 (es)
CR (2)	CR20180222A (es)
CY (1)	CY1117655T1 (es)
DK (1)	DK2575463T3 (es)
DO (3)	DOP2012000298A (es)
EC (1)	ECSP12012348A (es)
ES (2)	ES2666181T3 (es)
GT (1)	GT201200315A (es)
HR (1)	HRP20160714T1 (es)
HU (1)	HUE029231T2 (es)
IL (2)	IL222831A (es)
ME (1)	ME02452B (es)
MX (1)	MX337104B (es)
MY (1)	MY165427A (es)
NZ (1)	NZ603284A (es)
PE (2)	PE20130221A1 (es)
PH (3)	PH12012502277A1 (es)
PL (1)	PL2575463T3 (es)
PT (1)	PT2575463T (es)
RS (1)	RS54892B1 (es)
RU (1)	RU2567857C2 (es)
SG (3)	SG10201700115RA (es)
SI (1)	SI2575463T1 (es)
TW (1)	TWI520960B (es)
UA (1)	UA109278C2 (es)
UY (1)	UY33408A (es)
WO (1)	WO2011150016A1 (es)
ZA (1)	ZA201208727B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120156134A1 (en)	2007-12-20	2012-06-21	Shayne Squires	Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US8563735B2 (en)	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
UY32668A (es) *	2009-05-26	2010-12-31	Abbott Lab	Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
US8546399B2 (en) *	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en)	2009-05-26	2022-10-06	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2632436B1 (en)	2010-10-29	2018-08-29	Abbvie Inc.	Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ708508A (en)	2010-11-23	2016-06-24	Abbvie Bahamas Ltd	Methods of treatment using selective bcl-2 inhibitors
US20140189897A1 (en)	2011-06-21	2014-07-03	Mayo Foundation For Medical Education And Research	Transgenic animals capable of being induced to delete senescent cells
BR112014014529A2 (pt)	2011-12-13	2019-09-24	Buck Inst For Res On Aging	métodos para melhorar terapias médicas
US20150064137A1 (en)	2012-04-17	2015-03-05	Kythera Biopharmaceuticals, Inc.	Use of engineered viruses to specifically kill senescent cells
JP6225187B2 (ja) *	2012-08-13	2017-11-01	アッヴィ・インコーポレイテッド	アポトーシス誘発剤
US9901081B2 (en)	2012-08-23	2018-02-27	Buck Institute For Research On Aging	Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en)	2012-08-23	2018-02-27	Buck Institute For Research On Aging	Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
MX2015002947A (es)	2012-09-07	2015-09-23	Genentech Inc	Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
CN105102000B (zh)	2012-11-01	2021-10-22	无限药品公司	使用pi3激酶亚型调节剂的癌症疗法
AR095265A1 (es)	2013-03-13	2015-09-30	Abbvie Inc	Procesos para la preparación de un agente inductor de la apoptosis
BR122021025053B1 (pt) *	2013-03-13	2022-09-06	Abbvie Inc	Processo para a preparação de um agente indutor de apoptose
FR3008979B1 (fr) *	2013-07-23	2015-07-24	Servier Lab	Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015116735A1 (en)	2014-01-28	2015-08-06	Mayo Foundation For Medical Education And Research	Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en)	2014-01-28	2019-06-25	Mayo Foundation For Medical Education And Research	Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en)	2014-01-28	2019-09-05	Buck Institute for Research and Aging	Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
CA2939121C (en)	2014-01-28	2020-11-24	Mayo Foundation For Medical Education And Research	Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US9238652B2 (en)	2014-03-04	2016-01-19	Abbvie Inc.	Processes for the preparation of an apoptosis-inducing agent
PT3203840T (pt)	2014-10-06	2020-10-27	Vertex Pharma	Moduladores do regulador da condutância transmembranar da fibrose quística
US10195213B2 (en)	2015-03-13	2019-02-05	Unity Biotechnology, Inc.	Chemical entities that kill senescent cells for use in treating age-related disease
WO2017063572A1 (zh) *	2015-10-13	2017-04-20	苏州晶云药物科技有限公司	细胞凋亡诱导剂的新晶型及其制备方法
CN106957315B (zh) *	2016-01-08	2019-08-13	中国人民解放军第二军医大学	N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
US10738030B2 (en)	2016-03-31	2020-08-11	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20170300968A1 (en) *	2016-04-14	2017-10-19	Nb Portals, Llc	Method and system for disseminating information over a communication network
AU2017305508B2 (en) *	2016-08-05	2021-01-07	The Regents Of The University Of Michigan	N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
LT3519401T (lt)	2016-09-30	2021-11-25	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es)	2016-12-09	2022-09-30	Vertex Pharma	Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
US11053239B2 (en)	2017-01-07	2021-07-06	Fochon Pharmaceuticals, Ltd.	Compounds as BLC-2-selective apoptosis-inducing agents
WO2018157803A1 (zh) *	2017-02-28	2018-09-07	苏州科睿思制药有限公司	维奈妥拉的晶型及其制备方法
SI3612531T1 (sl)	2017-04-18	2022-11-30	Shanghai Fochon Pharmaceutical Co., Ltd.	Sredstva, ki sprožajo apoptozo
CN108794358B (zh) *	2017-04-27	2022-08-12	中国人民解放军第二军医大学	取代苯磺酰基类化合物及其制备药物的用途
CA3066084A1 (en)	2017-06-08	2018-12-13	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
AU2018304168B2 (en)	2017-07-17	2023-05-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CN111051280B (zh)	2017-08-02	2023-12-22	弗特克斯药品有限公司	制备吡咯烷化合物的方法
CN107501260B (zh) *	2017-08-14	2019-08-13	郑州大学第一附属医院	一种Bcl-2抑制剂venetoclax以及中间体的制备方法
CA3073446A1 (en)	2017-08-23	2019-02-28	Newave Pharmaceutical Inc.	Bcl-2 inhibitors
CN107445958A (zh) *	2017-09-19	2017-12-08	上海泓博智源医药股份有限公司	一种abt‑199中间体的制备方法
TWI719349B (zh)	2017-10-19	2021-02-21	美商維泰克斯製藥公司	Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr)	2017-12-08	2020-10-14	Vertex Pharma	Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
AU2019207616A1 (en)	2018-01-10	2020-07-09	Recurium Ip Holdings, Llc	Benzamide compounds
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
WO2019161221A2 (en)	2018-02-16	2019-08-22	Abbvie Inc.	Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
SI3788042T1 (sl)	2018-04-29	2025-06-30	Beigene Switzerland Gmbh	Zaviralci BCL-2
EP3672594B1 (en)	2018-07-31	2021-09-29	Ascentage Pharma (Suzhou) Co., Ltd.	Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
AU2019315466B2 (en)	2018-07-31	2022-05-19	Ascentage Pharma (Suzhou) Co., Ltd.	Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
TWI725488B (zh)	2018-07-31	2021-04-21	大陸商蘇州亞盛藥業有限公司	Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
CN114522167A (zh)	2018-07-31	2022-05-24	苏州亚盛药业有限公司	Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
WO2020041405A1 (en)	2018-08-22	2020-02-27	Newave Pharmaceutical Inc.	Bcl-2 inhibitors
CN112661751B (zh) *	2019-10-16	2024-06-14	南京天印健华医药科技有限公司	作为bcl-2抑制剂的杂环化合物
WO2021110102A1 (en) *	2019-12-02	2021-06-10	Beigene, Ltd.	Methods of cancer treatment using bcl-2 inhibitor
WO2021208963A1 (en)	2020-04-15	2021-10-21	Beigene, Ltd.	Bcl-2 inhibitor
WO2021231486A1 (en) *	2020-05-13	2021-11-18	Unity Biotechnology, Inc.	Cancer treatment by senescence induction followed by a senolytic
CN114736203A (zh) *	2021-01-07	2022-07-12	南京天印健华医药科技有限公司	作为bcl-2抑制剂的杂环化合物
EP4353722A4 (en) *	2021-06-04	2025-06-18	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phosphate of trifluoromethyl-substituted sulfonamide compound

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY115155A (en)	1993-09-09	2003-04-30	Upjohn Co	Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en)	1995-09-15	2004-01-14	PHARMACIA & UPJOHN COMPANY	Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
DE19830430A1 (de) *	1998-07-08	2000-01-13	Hoechst Marion Roussel De Gmbh	Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en)	1999-07-30	1999-09-29	Biochemie Gmbh	Organic compounds
AR031130A1 (es) *	2000-09-20	2003-09-10	Abbott Lab	N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en)	2000-09-20	2004-04-13	Abbott Laboratories	N-acylsulfonamide apoptosis promoters
JP4336678B2 (ja)	2003-09-04	2009-09-30	株式会社日立超エル・エス・アイ・システムズ	半導体装置
US7973161B2 (en)	2003-11-13	2011-07-05	Abbott Laboratories	Apoptosis promoters
US8614318B2 (en) *	2003-11-13	2013-12-24	Abbvie Inc.	Apoptosis promoters
WO2005049593A2 (en) *	2003-11-13	2005-06-02	Abbott Laboratories	N-acylsulfonamide apoptosis promoters
PL1737850T3 (pl)	2004-04-19	2008-02-29	Symed Labs Ltd	Nowy sposób wytwarzania linezolidu i związków pokrewnych
DE602004020812D1 (de)	2004-07-20	2009-06-04	Symed Labs Ltd	Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en)	2004-09-29	2009-03-31	Amr Technology, Inc.	Cyclosporin analogues and their pharmaceutical uses
DK1888550T3 (da)	2005-05-12	2014-09-29	Abbvie Bahamas Ltd	Apoptosepromotorer
TW200716636A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
US7514068B2 (en)	2005-09-14	2009-04-07	Concert Pharmaceuticals Inc.	Biphenyl-pyrazolecarboxamide compounds
MX2009002422A (es)	2006-09-05	2009-03-20	Abbott Lab	Inhibidores bcl para tratar exceso de plaquetas.
US8796267B2 (en)	2006-10-23	2014-08-05	Concert Pharmaceuticals, Inc.	Oxazolidinone derivatives and methods of use
WO2008064116A2 (en)	2006-11-16	2008-05-29	Abbott Laboratories	Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
BRPI0807813A2 (pt)	2007-02-15	2014-08-05	Hoffmann La Roche	2-amino-oxazolinas como ligantes de taar1
US8536157B2 (en)	2007-04-13	2013-09-17	The University Of Melbourne	Non-steroidal compounds
WO2008131259A1 (en)	2007-04-19	2008-10-30	Concert Pharmaceuticals Inc.	Deuterated morpholinyl compounds
US7531685B2 (en)	2007-06-01	2009-05-12	Protia, Llc	Deuterium-enriched oxybutynin
WO2009035598A1 (en)	2007-09-10	2009-03-19	Concert Pharmaceuticals, Inc.	Deuterated pirfenidone
US20090118238A1 (en)	2007-09-17	2009-05-07	Protia, Llc	Deuterium-enriched alendronate
US20090082471A1 (en)	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched fingolimod
US20090088416A1 (en)	2007-09-26	2009-04-02	Protia, Llc	Deuterium-enriched lapaquistat
EP2209774A1 (en)	2007-10-02	2010-07-28	Concert Pharmaceuticals Inc.	Pyrimidinedione derivatives
WO2009051782A1 (en)	2007-10-18	2009-04-23	Concert Pharmaceuticals Inc.	Deuterated etravirine
US20090105338A1 (en)	2007-10-18	2009-04-23	Protia, Llc	Deuterium-enriched gabexate mesylate
AU2008317375B2 (en)	2007-10-26	2013-02-28	Concert Pharmaceuticals, Inc.	Deuterated darunavir
KR101585848B1 (ko)	2007-11-16	2016-01-15	애브비 인코포레이티드	관절염의 치료 방법
UA108193C2 (uk) *	2008-12-04	2015-04-10		Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) *	2008-12-04	2010-06-24	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) *	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
RU2497822C2 (ru) *	2008-12-05	2013-11-10	Эббви Инк.	Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
NZ593593A (en) *	2009-01-19	2013-11-29	Abbvie Inc	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en)	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UY32668A (es) *	2009-05-26	2010-12-31	Abbott Lab	Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes

2011
- 2011-05-09 TW TW100116213A patent/TWI520960B/zh not_active IP Right Cessation
- 2011-05-25 CA CA2798765A patent/CA2798765C/en not_active Expired - Fee Related
- 2011-05-25 AU AU2011258350A patent/AU2011258350B2/en not_active Ceased
- 2011-05-25 JP JP2013512188A patent/JP5782508B2/ja not_active Expired - Fee Related
- 2011-05-25 RS RS20160487A patent/RS54892B1/sr unknown
- 2011-05-25 HU HUE11787299A patent/HUE029231T2/en unknown
- 2011-05-25 HR HRP20160714TT patent/HRP20160714T1/hr unknown
- 2011-05-25 SG SG10201700115RA patent/SG10201700115RA/en unknown
- 2011-05-25 WO PCT/US2011/037849 patent/WO2011150016A1/en not_active Ceased
- 2011-05-25 CN CN201510086898.3A patent/CN104961771B/zh active Active
- 2011-05-25 PH PH1/2012/502277A patent/PH12012502277A1/en unknown
- 2011-05-25 NZ NZ603284A patent/NZ603284A/en not_active IP Right Cessation
- 2011-05-25 CN CN201180025920.3A patent/CN102939009B/zh active Active
- 2011-05-25 EP EP11787299.4A patent/EP2575463B1/en active Active
- 2011-05-25 PE PE2012002219A patent/PE20130221A1/es active IP Right Grant
- 2011-05-25 KR KR1020127033740A patent/KR101800167B1/ko not_active Expired - Fee Related
- 2011-05-25 SG SG2012081824A patent/SG185447A1/en unknown
- 2011-05-25 SI SI201130872A patent/SI2575463T1/sl unknown
- 2011-05-25 PL PL11787299.4T patent/PL2575463T3/pl unknown
- 2011-05-25 PE PE2017000244A patent/PE20170465A1/es unknown
- 2011-05-25 SG SG10201700112VA patent/SG10201700112VA/en unknown
- 2011-05-25 KR KR1020177018800A patent/KR101850679B1/ko not_active Expired - Fee Related
- 2011-05-25 RU RU2012156940/04A patent/RU2567857C2/ru active
- 2011-05-25 EP EP17199100.3A patent/EP3312178A1/en not_active Withdrawn
- 2011-05-25 MX MX2012013704A patent/MX337104B/es active IP Right Grant
- 2011-05-25 BR BR112012029733-3A patent/BR112012029733B1/pt not_active IP Right Cessation
- 2011-05-25 ME MEP-2016-126A patent/ME02452B/me unknown
- 2011-05-25 ES ES16161558.8T patent/ES2666181T3/es active Active
- 2011-05-25 UA UAA201214905A patent/UA109278C2/ru unknown
- 2011-05-25 PT PT117872994T patent/PT2575463T/pt unknown
- 2011-05-25 CR CR20180222A patent/CR20180222A/es unknown
- 2011-05-25 MY MYPI2012700921A patent/MY165427A/en unknown
- 2011-05-25 US US13/115,376 patent/US9006247B2/en active Active
- 2011-05-25 ES ES11787299.4T patent/ES2574855T3/es active Active
- 2011-05-25 DK DK11787299.4T patent/DK2575463T3/en active
- 2011-05-25 UY UY33408A patent/UY33408A/es not_active Application Discontinuation
- 2011-05-25 EP EP16161558.8A patent/EP3091017B1/en active Active
- 2011-05-26 AR ARP110101806 patent/AR081552A1/es active IP Right Grant
2012
- 2012-11-01 IL IL222831A patent/IL222831A/en active IP Right Grant
- 2012-11-20 ZA ZA2012/08727A patent/ZA201208727B/en unknown
- 2012-11-22 DO DO2012000298A patent/DOP2012000298A/es unknown
- 2012-11-23 CL CL2012003285A patent/CL2012003285A1/es unknown
- 2012-11-23 GT GT201200315A patent/GT201200315A/es unknown
- 2012-12-13 CO CO12226070A patent/CO6640275A2/es active IP Right Grant
- 2012-12-18 CR CR20120648A patent/CR20120648A/es unknown
- 2012-12-20 EC ECSP12012348 patent/ECSP12012348A/es unknown
2014
- 2014-07-28 IL IL233832A patent/IL233832B/en active IP Right Grant
2015
- 2015-03-11 US US14/645,378 patent/US9403822B2/en active Active
2016
- 2016-05-04 DO DO2016000100A patent/DOP2016000100A/es unknown
- 2016-06-10 PH PH12016501126A patent/PH12016501126A1/en unknown
- 2016-06-15 CY CY20161100529T patent/CY1117655T1/el unknown
- 2016-06-30 US US15/199,782 patent/US20170096424A1/en not_active Abandoned
2017
- 2017-08-09 DO DO2017000186A patent/DOP2017000186A/es unknown
2018
- 2018-06-13 PH PH12018501264A patent/PH12018501264A1/en unknown
- 2018-11-28 US US16/203,509 patent/US20190315737A1/en not_active Abandoned
2019
- 2019-10-24 US US16/663,285 patent/US20200277291A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2012156940A (ru)	2014-07-10
CA2798765C (en)	2018-10-23
ES2574855T3 (es)	2016-06-22
DOP2017000186A (es)	2017-09-15
CR20180222A (es)	2018-06-05
CN102939009A (zh)	2013-02-20
ZA201208727B (en)	2013-07-31
IL233832B (en)	2018-05-31
US20120028925A1 (en)	2012-02-02
ES2666181T3 (es)	2018-05-03
HRP20160714T1 (hr)	2016-07-15
US20170096424A1 (en)	2017-04-06
RS54892B1 (sr)	2016-10-31
PH12016501126B1 (en)	2017-06-14
KR101850679B1 (ko)	2018-04-20
NZ603284A (en)	2015-01-30
CN104961771B (zh)	2018-02-02
PH12012502277A1 (en)	2013-02-11
MX2012013704A (es)	2013-03-21
CY1117655T1 (el)	2017-05-17
CA2798765A1 (en)	2011-12-01
GT201200315A (es)	2014-07-11
DK2575463T3 (en)	2016-07-25
IL222831A (en)	2014-08-31
EP2575463A1 (en)	2013-04-10
PL2575463T3 (pl)	2016-10-31
RU2567857C2 (ru)	2015-11-10
PE20170465A1 (es)	2017-05-18
KR20170083164A (ko)	2017-07-17
HUE029231T2 (en)	2017-02-28
MY165427A (en)	2018-03-22
DOP2016000100A (es)	2016-05-31
SG10201700115RA (en)	2017-02-27
SI2575463T1 (sl)	2016-11-30
US20200277291A1 (en)	2020-09-03
MX337104B (es)	2016-02-09
EP2575463B1 (en)	2016-03-30
WO2011150016A1 (en)	2011-12-01
PE20130221A1 (es)	2013-04-04
EP3312178A1 (en)	2018-04-25
HK1182593A1 (zh)	2013-12-06
EP2575463A4 (en)	2013-11-27
BR112012029733A2 (pt)	2017-06-13
CN102939009B (zh)	2015-03-25
IL233832A0 (en)	2014-09-30
JP5782508B2 (ja)	2015-09-24
PH12016501126A1 (en)	2017-06-14
KR101800167B1 (ko)	2017-11-22
SG10201700112VA (en)	2017-03-30
US20150246914A1 (en)	2015-09-03
US9006247B2 (en)	2015-04-14
UA109278C2 (uk)	2015-08-10
PT2575463T (pt)	2016-07-13
IL222831A0 (en)	2012-12-31
CR20120648A (es)	2013-04-03
UY33408A (es)	2011-12-30
TWI520960B (zh)	2016-02-11
EP3091017B1 (en)	2018-01-17
JP2013526612A (ja)	2013-06-24
TW201141862A (en)	2011-12-01
CO6640275A2 (es)	2013-03-22
PH12018501264A1 (en)	2019-07-01
KR20130086954A (ko)	2013-08-05
DOP2012000298A (es)	2018-04-30
SG185447A1 (en)	2012-12-28
AU2011258350A1 (en)	2012-11-22
ECSP12012348A (es)	2013-04-30
CN104961771A (zh)	2015-10-07
US9403822B2 (en)	2016-08-02
US20190315737A1 (en)	2019-10-17
AU2011258350B2 (en)	2015-04-09
ME02452B (me)	2016-09-20
AR081552A1 (es)	2012-10-03
BR112012029733B1 (pt)	2020-12-01
EP3091017A1 (en)	2016-11-09

Publication	Publication Date	Title
CL2012003285A1 (es)	2013-10-04	Compuestos derivados de sulfonil-carbamoil-fenoxi-pirrolo-piridina, inhibidores de la actividad de proteinas anti-apoptoticas bcl-2; composicion farmaceutica; y metodo para tratar cancer de vejiga, cancer de cerebro, cancer de mama, cancer de medula osea, cancer cervical y leucemia linfocitica cronica, entre otras enfermedades.
CL2011002949A1 (es)	2012-05-25	Compuestos derivados de fenil-sulfonil-amida o piridin-sulfonil-amida, inhibidores de la actividad de las proteinas bc1-2 anti-apoptoticas; composicion farmaceutica, utiles para el tratamiento del cancer de vejiga, cerebro, mama, medula osea y cuello uterino, entre otros.
CL2012003286A1 (es)	2014-02-21	Compuestos derivados de heerociclos sustituidos, inductores de apoptosis; composicion farmaceutica; y su uso para el tratamiento de diversos cancer, tales como vejiga, cerebro, mamas, medula osea, hepatocelular, linfoma, leucemia linfoblastica, entre otros
CL2015001818A1 (es)	2015-10-02	Compuestos derivados de azaindol, inhibidores de las proteina quinasas; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer de higado, cancer pancreatico, cancer de pulmon, cancer de mama, leucemias, entre otras.
FR2968305B1 (fr)	2014-02-28	Procede de preparation d'un gel reticule
PH12015501744A1 (en)	2015-12-07	Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
CL2008000348A1 (es)	2008-08-18	Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
CL2014000922A1 (es)	2014-08-18	Compuestos derivados de dihidroisoquinolinas o sus sales, como inhibidores de la actividad de las proteinas antiapoptoticas bcl-xl; composicion farmaceutica que los comprende, util para el tratamiento de cancer de vejiga, de cerebro, de mama, de medula osea, colorrectal, de esofago, de ovario, leucemia linfocitica cronica, o cancer de bazo, entre otros.
FR2968306B1 (fr)	2014-02-28	Procede de preparation d'un gel reticule
BR112014005091A2 (pt)	2017-06-13	composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
PH12013500970A1 (en)	2013-07-08	Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers, and liver health maintenance
HK1199290A1 (en)	2015-06-26	Methods and compositions for the treatment and diagnosis of breast cancer
MX367425B (es)	2019-08-21	Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
EA201391171A1 (ru)	2014-11-28	Формы рифаксимина и их применение
BR112012005343A2 (pt)	2016-03-22	sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer
EP2666469A4 (en)	2014-07-09	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MELASMA AND METHOD OF MANUFACTURING THEREOF
WO2012125981A3 (en)	2012-11-15	Raf kinase inhibitors
SG11201508544VA (en)	2015-11-27	Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
EP2785871A4 (en)	2015-08-26	CTC BIOMARKET TEST FOR COMBATING BRAIN METETAS IN BREAST CANCER
BR112013016107A2 (pt)	2017-04-04	molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
FR2997085B1 (fr)	2015-05-29	Procede de preparation d'un gel reticule
FR2956816B1 (fr)	2012-05-18	Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
IL235429A0 (en)	2014-12-31	(r)-nifortal, its use in the treatment of infections and the preparation of (r) and (s)-nifortal
WO2013087929A3 (de)	2013-08-08	Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom
IL268757A (en)	2019-10-31	Pharmaceutical preparations containing 7-(H1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydroquinoline for the treatment of skin diseases and conditions